Zobrazeno 1 - 10
of 6 136
pro vyhledávání: '"pneumococcal disease"'
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 879-886 (2024)
Objectives The 13-valent (PCV13) and 10-valent (PCV10) pneumococcal conjugate vaccines missed non-inferiority for certain 7-valent (PCV7) serotypes in immunogenicity trials. This study examines the population-level IPD case trends for these serotypes
Externí odkaz:
https://doaj.org/article/b2af8fd431f24efa983b229a2a481989
Autor:
Shigeki Nakamura, Masashi Mikami, Tomoyuki Hayamizu, Naohiro Yonemoto, Camille Moyon, Mark Gouldson, Catriona Crossan, Jeffrey Vietri, Kazumasa Kamei
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 546-560 (2024)
ABSTRACTBackground The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated bu
Externí odkaz:
https://doaj.org/article/5239dd86e93040829e02bc8ac2bf6317
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 12, Pp 2597-2615 (2024)
Abstract Introduction Given the recent approval and recommendation of V116, a 21-valent pneumococcal conjugate vaccine (PCV), in the United States (US), we evaluated the cost-effectiveness of using V116 versus the 20-valent PCV (PCV20) or the 15-vale
Externí odkaz:
https://doaj.org/article/d9c38c5e03ad48419eb1b806e1b05f51
Autor:
Jessica Weaver, Tianyan Hu, Bélène Podmore, Rosemarie Barnett, Dominik Obermüller, Wolfgang Galetzka, Nawab Qizilbash, Dennis Haeckl, Thomas Weiss, Salini Mohanty, Meghan White, Timo Boellinger
Publikováno v:
BMC Pediatrics, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background Novel, expanded valency pneumococcal conjugate vaccines (PCVs) are in development to reduce the burden of pneumococcal disease (PD) in children. To understand the potential value of new vaccines in Germany, this study estimated th
Externí odkaz:
https://doaj.org/article/a4092095f5664b848c1e6e02f8fee0ae
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-14 (2024)
Abstract Background Streptococcus pneumoniae is a major cause of mortality globally. The introduction of pneumococcal conjugate vaccines (PCVs) has reduced the incidence of the targeted serotypes significantly, but expansion of non-targeted serotypes
Externí odkaz:
https://doaj.org/article/d53e7a721b12438496c7014fea3bcdc2
Autor:
Charles Reynard, James Campling, Adam L Gordon, George Kassianos, Hui-Hsuan Liu, Alex Richter, Andrew Vyse, Dexter J Wiseman, Hannah Wright, Gillian Ellsbury
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 1052-1067 (2024)
Introduction Vaccine-preventable respiratory infections (VPRI) including those caused by Streptococcus pneumoniae, influenza, respiratory syncytial virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pose substantial challenges to
Externí odkaz:
https://doaj.org/article/344fc650b9154e7594b134655a60466b
Autor:
Elmira Flem, Celine Mouawad, Arto A. Palmu, Heather Platt, Kelly D. Johnson, E. David McIntosh, Jacobo Abadi, Ulrike K. Buchwald, Kristen Feemster
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 997-1010 (2024)
Introduction Infant immunization programs using pneumococcal conjugate vaccines (PCVs) have reduced the rates of pneumococcal disease through direct vaccine-induced protection in vaccinated children and through indirect protection in non-vaccinated c
Externí odkaz:
https://doaj.org/article/5fc4834eb542452fa1ce111541ca8cee
Autor:
Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, Naohiro Yonemoto, Junko Morii, Johnna Perdrizet, Kazumasa Kamei
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 485-497 (2024)
Background The Japanese National Immunization Program currently includes the pediatric 13 valent pneumococcal conjugate vaccine (PCV13) to prevent pneumococcal infections. We aimed to evaluate the cost-effectiveness of 20-valent PCV (PCV20) as a pedi
Externí odkaz:
https://doaj.org/article/71b05513c01b4d099126da3986cf1959
Autor:
Xiang Guo, Juan Li, Jing Qiu, Rui Zhang, Jia Ren, Zhuoying Huang, Zhi Li, Xiufang Liang, Fang Lan, Juan Chen, Fang Huang, Xiaodong Sun
Publikováno v:
Expert Review of Vaccines, Vol 23, Iss 1, Pp 237-245 (2024)
ABSTRACTBackground Pneumococcal vaccines are effective in preventing pneumococcal diseases in adults. The evaluation of the antibodies persistence to the 23-valent pneumococcal polysaccharide vaccine (PPV23) could provide evidence on PPV23 revaccinat
Externí odkaz:
https://doaj.org/article/e3d517bfcb434318bc1f8acd2e29411e
Approaches to vaccination of adults against pneumococcal disease in different countries of the world
Publikováno v:
Журнал инфектологии, Vol 16, Iss 2, Pp 5-16 (2024)
Various pneumococcal vaccines are available worldwide, differing in the range of serotypes coverage and type of vaccine, which determine different mechanisms of action and postvaccinal immunity. Vaccination against pneumococcal infection is recommend
Externí odkaz:
https://doaj.org/article/05d2d9709e324b5dac9d55ef5702dc7f